**Question:** Antipsychotics are safer in the patient with

A. Parkinson's disease
B. Alzheimer's disease
C. Dementia with Lewy bodies
D. Schizophrenia

**Correct Answer:** D. Schizophrenia

**Core Concept:** Antipsychotics are a class of medications primarily used to treat psychotic disorders, particularly schizophrenia. They primarily work by blocking dopamine receptors, specifically D2 receptors, in the brain.

**Why the Correct Answer is Right:** Antipsychotics are generally considered safer in patients with schizophrenia because these patients have a higher risk of developing tardive dyskinesia (a movement disorder) when exposed to long-term neuroleptic treatment. Tardive dyskinesia results from chronic dopamine blockade, particularly at the D2 receptors in the basal ganglia. In contrast, the other options pose different safety concerns.

**Why Each Wrong Option is Incorrect:**

A. Parkinson's disease: Patients with Parkinson's disease present with hypodopaminergic state (low dopamine levels). Long-term antipsychotic use would exacerbate the existing dopaminergic deficit, leading to worsening of motor symptoms and increased risk of extrapyramidal side effects like akathisia (restlessness) and Parkinsonism (resting tremors, rigidity, and gait disturbances).

B. Alzheimer's disease: Patients with Alzheimer's disease have a higher risk of developing neuroleptic malignant syndrome (NMS) when exposed to antipsychotics. NMS is a severe life-threatening condition characterized by hyperthermia, muscle rigidity, autonomic instability, and altered mental status.

C. Dementia with Lewy bodies: Similar to Alzheimer's disease, patients with dementia with Lewy bodies also have a higher risk of developing neuroleptic malignant syndrome when exposed to antipsychotics.

**Clinical Pearl:** When choosing an antipsychotic for a patient with a psychiatric disorder, consider the underlying neurobiological condition and its potential interactions with antipsychotic drugs. In general, antipsychotics are safer in patients with schizophrenia due to the reduced risk of tardive dyskinesia compared to other neurodegenerative disorders. However, individual patient conditions and comorbidities should also be taken into account when selecting an antipsychotic.